Antibody against human L1CAM protein and its application
By developing specific anti-human L1CAM protein antibodies, the problem of difficulty in recognition and capture of neuronal exosomes is solved, and efficient diagnosis of neurodegenerative diseases is achieved.
Patent Information
- Application Number
- CN202411216972.4
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Filing Date
- 2024-09-02
- Publication Date
- 2024-11-26
- Estimated Expiration
- 2044-09-02
AI Technical Summary
Existing technologies are difficult to effectively identify and capture exosomes from neurons, resulting in difficulty in diagnosis of neurodegenerative diseases such as Alzheimer's disease and Parkinson's disease.
An antibody or antigen-binding fragment of its specific anti-human L1CAM protein has been developed, including specific amino acid sequences of heavy and light chain variable regions, capable of specifically identifying and binding to L1CAM protein for capture of neuronal exosomes. and diagnosis.
The antibody shows strong binding activity, capable of effectively identifying and capturing neuronal exosomes, providing a novel diagnostic tool for screening and diagnosing neurodegenerative diseases.
Smart Images

Figure CN118725120B_ABST
Abstract
Description
Technical Field
[0001] The invention belongs to the field of biotechnology and relates to an antibody against human L1CAM protein and application thereof. Background Art
[0002] Human L1CAM (L1 cell adhesion molecule) protein is a neural adhesion protein in the immunoglobulin superfamily, existing in the form of membrane protein and free protein. L1CAM is a 200-220 kDa transmembrane glycoprotein in the immunoglobulin (Ig) superfamily, consisting of 6 Ig-like domains and 5 fibronectin type III repeats, followed by a transmembrane region and a highly conserved cytoplasmic tail region. L1CAM protein plays an important role in multiple neural development processes such as neuronal adhesion and migration, neurite outgrowth, axon guidance and bundling, and synapse formation. L1CAM antibody can recognize and bind to L1CAM protein, and can specifically recognize exosomes derived from neurons. It can be used as a key substance for the specific capture of neuronal exosomes. The captured neuronal exosomes can be used as samples for the diagnosis of neurodegenerative diseases.
[0003] Therefore, the development of a new generation of anti-human L1CAM proteins has important scientific and application value. Summary of the invention
[0004] The object of the present invention is to provide an antibody or an antigen-binding fragment thereof against human L1CAM protein, and based on the antibody or the antigen-binding fragment thereof, provide a use thereof.
[0005] In order to achieve the above object, the present invention adopts the following technical solutions:
[0006] The first aspect of the present invention provides an antibody or an antigen-binding fragment thereof that has binding specificity to human L1CAM protein.
[0007] Further, the antibody comprises a heavy chain variable region and a light chain variable region, the heavy chain variable region comprises HCDR1, HCDR2 and HCDR3 in the heavy chain variable region as shown in SEQ ID NO:1; the light chain variable region comprises LCDR1, LCDR2 and LCDR3 in the light chain variable region as shown in SEQ ID NO:2.
[0008] In the present invention, the term "antibody" refers to any form of an antibody that exhibits a desired biological activity (e.g., inhibiting the binding of a ligand to its receptor or by inhibiting ligand-induced receptor signal transduction). Therefore, "antibody" is used in its broadest sense and explicitly includes, but is not limited to, monoclonal antibodies (including full-length monoclonal antibodies), polyclonal antibodies and multispecific antibodies (e.g., bispecific antibodies), fully human, humanized, primatized, chimeric antibodies, single-chain antibodies, etc.
[0009] In the present invention, the term "antigen-binding fragment" refers to a portion of an antibody, such as F(ab') 2 、F(ab) 2 , Fab', Fab, Fv, scFv, etc. Regardless of their structure, antibody fragments bind to the same antigen recognized by the intact antibody. The term "antigen binding fragment" includes aptamers, spiegelmers, and bivalent antibodies. The term "antigen binding fragment" also includes any synthetic or genetically engineered protein that acts as an antibody by binding to a specific antigen to form a complex.
[0010] In the present invention, a "light chain variable region (VL)" or "heavy chain variable region (VH)" consists of a "framework" region interspersed with three "complementarity determining regions (CDRs)". The framework region is used to adjust the CDRs for specific binding to antigenic epitopes. The CDRs contain the amino acid residues in the antibody that are primarily responsible for antigen binding. From the amino terminus to the carboxyl terminus, both the VL and VH domains contain the following framework (FR) regions and CDR regions: FR1, CDR1, FR2, CDR2, FR3, CDR3, and FR4.
[0011] In the present invention, "CDR" refers to the "complementarity determining region" within the variable sequence of an antibody. There are three CDRs in each variable region of the heavy chain and the light chain, which are specifically designated as "HCDR1", "HCDR2", "HCDR3", "LCDR1", "LCDR2" and "LCDR3" for each variable region. "Framework" (FR) or "framework sequence" in the present invention refers to the sequence of the variable region minus the CDR. Because the precise definition of CDR sequences can be determined by different systems, the meaning of framework sequences is subject to correspondingly different specifications. The three complementarity determining regions HCDR1, HCDR2, HCDR3 of the heavy chain variable region, the six CDRs of the complementarity determining regions LCDR1, LCDR2, LCDR3 of the light chain variable region (also divide the framework regions on the heavy chain and light chain into four subregions (FR1, FR2, FR3 and FR4) on each chain, wherein CDR1 is located between FR1 and FR2, CDR2 is located between FR2 and FR3, and CDR3 is located between FR3 and FR4. In the absence of designation of specific subregions as FR1, FR2, FR3 and FR4, the framework region as indicated by others represents the FRs combined within the variable region of a single, naturally occurring immunoglobulin chain. As used in the present invention, FR represents one of the four subregions, and FR represents two or more of the four subregions that make up the framework region.
[0012] A variety of schemes are known in the art for determining the CDR sequences in a given VH or VL amino acid sequence: Kabat complementarity determining regions (CDRs) are determined based on sequence variability and are the most commonly used (Kabat et al., Sequences of Proteins of Immunological Interest, 5th edition, Public Health Service, National Institutes of Health, Bethesda, Md. (1991)), while Chothia refers to the position of structural loops (Chothia et al., (1987) J. Mol. Biol. 196:901-917; Chothia et al. (1989) Nature 342:877-883), AbM CDRs are a compromise between Kabat CDRs and Chothia structural loops and are used by Oxford Molecular's AbM antibody modeling software, and "Contact" CDRs are based on analysis of available complex crystal structures. Depending on different CDR determination schemes, the sequences in these CDRs may be different.
[0013] The CDR of the antibody of the present invention can be manually assessed to determine the boundaries according to any scheme or combination thereof in the art. Unless otherwise specified, in the present invention, the term "CDR" or "CDR sequence" encompasses CDR sequences determined in any of the above ways.
[0014] Those skilled in the art will appreciate that the classes of antibody heavy chains include gamma, mu, alpha, delta or epsilon (γ, μ, α, δ, ε), among which there are also some subclasses (e.g., γ 1-γ 4). The nature of the chain determines the "class" of the antibody, IgG, IgM, IgA, IgD or IgE, respectively. Immunoglobulin subclasses (isotypes), such as IgG1, IgG2, IgG3, IgG4, IgG5, etc., have been fully characterized and the functional specificity conferred is also known. All immunoglobulin classes are within the scope of protection disclosed in the present invention.
[0015] Further, the heavy chain variable region comprises the amino acid sequence shown in SEQ ID NO:1, or an amino acid sequence that is at least 90% identical to the amino acid sequence shown in SEQ ID NO:1, or a sequence having one or more amino acid substitutions, deletions or insertions or any combination thereof compared to the amino acid sequence shown in SEQ ID NO:1.
[0016] Further, the light chain variable region comprises the amino acid sequence shown in SEQ ID NO:2, or an amino acid sequence that is at least 90% identical to the amino acid sequence shown in SEQ ID NO:2, or a sequence having one or more amino acid substitutions, deletions or insertions or any combination thereof compared to the amino acid sequence shown in SEQ ID NO:2.
[0017] In the present invention, the term "identity" refers to the sequence similarity with the amino acid sequence used in the present invention. In order to determine the sequence identity, a sequence alignment can be performed, which can be performed in the various ways known to those skilled in the art, for example, using BLAST, ALIGN, NEEDLE or Megalign (DNASTAR) software, etc. Those skilled in the art can determine the appropriate parameters for comparison, including any algorithm required for realizing optimal comparison in the full-length sequence compared. Therefore, an amino acid sequence that is at least 90%, 99.1%, 99.2%, 99.3%, 99.4%, 99.5%, 99.6%, 99.7%, 99.8% or 99.9% identical to the sequence of the present invention is within the scope of protection of the present invention.
[0018] In the present invention, the antibody sequence obtained by modification also belongs to the protection scope of the present invention. The term "modification" refers to any chemical modification of the amino acid sequence, such as substitution, deletion, insertion and / or addition of amino acids. The term "substitution" refers to the replacement of one or more amino acids by different amino acids. "Deletion" refers to the reduction of one or more amino acids in the amino acid sequence. "Insertion" or "addition" refers to the change in the amino acid sequence resulting in the increase of one or more amino acids compared to the naturally occurring molecule. It should be noted that in the modified antibodies provided by the present invention, the modification preferably occurs in a region outside the variable region, such as in the framework region or constant region of the antibody, and the modified antibody still retains the desired functional properties of the antibody of the present invention or its antigen-binding fragment, or has improved antigen-binding properties.
[0019] Furthermore, the antibody includes a monoclonal antibody, a polyclonal antibody, a chimeric antibody, a humanized antibody or a murine antibody.
[0020] In the present invention, the term "monoclonal antibody", sometimes also referred to as "monoantibody" or Ab, refers to an immunoglobulin obtained from a pure line of cells, having the same structure and chemical properties, and specific to a single antigenic determinant. Monoclonal antibodies are different from conventional polyclonal antibody preparations (usually different antibodies against different determinants), and each monoclonal antibody is directed against a single determinant on the antigen. In addition to their specificity, the advantage of monoclonal antibodies is that they are obtained through hybridoma or recombinant engineering cell culture and are not mixed with other immunoglobulins. This characteristic is in contrast to polyclonal antibody preparations, which generally include antibodies against different antigenic determinants. The modifier "monoclonal" indicates the characteristic of the antibody, which is obtained from a homogeneous antibody population, but this should not be interpreted as requiring any special method to produce the antibody.
[0021] In the present invention, the term "chimeric antibody" generally refers to an antibody in which a portion of each heavy chain or light chain amino acid sequence is homologous to the corresponding amino acid sequence in an antibody from a specific species, or belongs to a specific category, while the remaining segments of the chain are homologous to the corresponding sequence in another species. For example, the variable regions of the light chain and the heavy chain are both from the variable regions of antibodies of one animal species (such as mice, rats, etc.), while the constant portion is homologous to the antibody sequence from another species (such as humans). For example, to obtain a chimeric antibody, a non-human B cell or hybridoma cell can be used to produce a variable region, and the constant region combined therewith is from a human. The variable region has the advantage of being easy to prepare, and its specificity is not affected by the source of the constant region combined therewith. At the same time, since the constant region of a chimeric antibody can be derived from humans, the possibility of chimeric antibodies triggering an immune response when injected is lower than that of antibodies using a non-human constant region.
[0022] In the present invention, the term "humanized antibody" generally refers to a chimeric antibody that contains less sequences from non-human immunoglobulins, thereby reducing the immunogenicity of heterologous antibodies when introduced into humans, while maintaining the complete antigen binding affinity and specificity of the antibody. Antibody humanization is a process that increases the proportion of human sequences in heterologous antibodies. Preferably, more than 85% of the variable regions in humanized antibodies are present, preferably 90%, further preferably 95%, such as 95%, 96%, 97%, 98%, or even more than 99% of human genes are humanized antibodies. It is understandable that the framework region or constant region in a humanized antibody may be partially or entirely encoded by human antibody genes. When there are less than 85% of human genes in the variable region of a humanized antibody, it is considered to be a chimeric antibody.
[0023] In the present invention, the term "murine antibody" generally refers to an antibody whose variable region framework and CDR region are derived from mouse germline immunoglobulin sequences. In addition, if the antibody comprises a constant region, it is also derived from mouse germline immunoglobulin sequences. In the present invention, the murine antibody may comprise amino acid residues not encoded by mouse germline immunoglobulin sequences, for example, mutations introduced by random mutations or point mutations in vitro or by somatic mutations in vivo.
[0024] Furthermore, the antigen-binding fragments include Fab, Fab', F(ab') 2 , Fv or single-chain Fv antibodies.
[0025] In the present invention, "Fab fragment" is composed of a light chain and the CH1 and variable region of a heavy chain. The heavy chain of a Fab molecule cannot form a disulfide bond with another heavy chain molecule.
[0026] In the present invention, the "Fc region" contains two heavy chain fragments including the CH2 and CH3 domains of an antibody. The two heavy chain fragments are held together by two or more disulfide bonds and the hydrophobic interaction of the CH3 domain.
[0027] In the present invention, the "Fv region" comprises the variable regions from both the heavy chain and the light chain, but lacks the constant region.
[0028] In the present invention, "single-chain Fv antibody" (or "scFv antibody") refers to an antibody fragment comprising the VH and VL domains of an antibody, wherein these domains are present in a single polypeptide chain. Generally speaking, the Fv polypeptide further comprises a polypeptide linker between the VH and VL domains, which enables the scFv to form the desired structure for antigen binding.
[0029] A second aspect of the present invention provides an antibody derivative.
[0030] Furthermore, the antibody derivative comprises the antibody or antigen-binding fragment thereof according to the first aspect of the present invention and an antibody marker.
[0031] Furthermore, the antibody markers include enzymes, fluorescein, isotopes, biotin, colloidal gold, chemiluminescent agents, and the like.
[0032] In the present invention, the term "antibody marker" mainly refers to combining a specific antibody with some chemical substances or biological molecules, so that the optical, radioactive or chemical properties of the antibody are changed, thereby facilitating the detection, location or purification of the target molecule.
[0033] In the present invention, enzyme labeling in antibody markers refers to combining an enzyme with an antibody and using the catalytic action of the enzyme to detect the target molecule. Commonly used enzymes include horseradish peroxidase (HRP), alkaline phosphatase (AP), etc. HRP-labeled antibodies are commonly used in experiments such as ELISA (enzyme-linked immunosorbent assay) to perform quantitative detection by reacting with a substrate to produce a color change.
[0034] In the present invention, the fluorescent label in the antibody marker refers to combining fluorescent dyes with antibodies and using fluorescent signals to detect target molecules. Commonly used fluorescent dyes include fluorescein, rhodamine, autofluorescent proteins, etc. Among them, fluorescein isothiocyanate (FITC) is one of the most commonly used fluoresceins, used in experiments such as immunohistochemistry.
[0035] In the present invention, isotope labeling refers to combining a radioactive isotope with an antibody and using radioactive decay to detect the target molecule. Commonly used radioactive isotopes include iodine-125, iodine-131, deuterium-3, etc.
[0036] In the present invention, biotin labeling refers to combining biotin with antibodies and using the combination of biotin and avidin or streptavidin to detect target molecules. Biotin can also be used to purify target molecules. The biotin-avidin system has been widely used in antigen analysis due to its high affinity and cascade amplification effect.
[0037] In the present invention, colloidal gold labeling refers to combining colloidal gold particles with antibodies and using the surface plasmon resonance of colloidal gold to detect target molecules. Colloidal gold can also be used for electron microscopy and optical microscopy detection. Due to its high electron density, colloidal gold labeling can be seen as dark brown particles under a microscope, and the detection results are intuitive and easy to interpret.
[0038] In the present invention, chemiluminescent labeling refers to directly labeling antibodies with chemiluminescent agents and detecting them through chemiluminescent reactions. Commonly used labeling luminescent agents are luminols.
[0039] In the present invention, antibody markers also include magnetic markers, which combine magnetic particles with antibodies and use magnetic signals to detect, separate or enrich target molecules. Commonly used magnetic particles include superparamagnetic ferrites and magnetic ions.
[0040] The third aspect of the present invention provides a nucleic acid molecule.
[0041] Furthermore, the nucleic acid molecule comprises a nucleotide sequence encoding a heavy chain variable region of the antibody or antigen-binding fragment thereof according to the first aspect of the present invention, and a nucleotide sequence encoding a light chain variable region of the antibody or antigen-binding fragment thereof according to the first aspect of the present invention.
[0042] Furthermore, the polynucleotide comprises the following nucleotide sequence:
[0043] The nucleotide sequences shown in SEQ ID NOs: 11, 12, and 13 respectively encode HCDR1, HCDR2, and HCDR3 of the heavy chain variable region of the antibody or antigen-binding fragment thereof according to the first aspect of the present invention;
[0044] The nucleotide sequences shown in SEQ ID NOs: 14, 15, and 16 respectively encode LCDR1, LCDR2, and LCDR3 of the light chain variable regions of the antibody or antigen-binding fragment thereof according to the first aspect of the present invention;
[0045] The nucleotide sequences shown in SEQ ID NOs: 9 and 10 respectively encode the heavy chain variable region and the light chain variable region of the antibody or antigen-binding fragment thereof according to the first aspect of the present invention.
[0046] In the present invention, the term "nucleic acid molecule" refers to DNA molecules and RNA molecules. Nucleic acid molecules can be single-stranded or double-stranded, but are preferably double-stranded DNA. A nucleic acid is "operably linked" when it is placed in a functional relationship with another nucleic acid sequence. For example, if a promoter or enhancer affects the transcription of a coding sequence, then the promoter or enhancer is operably linked to the coding sequence.
[0047] Standard molecular biology techniques can be used to obtain nucleic acid molecules of the present invention. Once the DNA fragments encoding the heavy chain variable region and the light chain variable region are obtained, these DNA fragments are further operated by standard recombinant DNA techniques, such as to convert the variable region genes into full-length antibody chain genes, Fab fragment genes or scFv genes. In these operations, the DNA fragments encoding the heavy chain variable region and the light chain variable region are operably connected to another DNA fragment encoding another protein, such as an antibody constant region or a flexible joint. Wherein, the term "operably connected" is intended to mean connecting two DNA fragments when used herein so that the amino acid sequences encoded by the two DNA fragments remain in the same reading frame (in-frame).
[0048] The fourth aspect of the present invention provides a vector or a host cell.
[0049] Furthermore, the vector comprises the nucleic acid molecule described in the third aspect of the present invention.
[0050] Furthermore, the host cell comprises the polynucleotide or the above-mentioned vector described in the third aspect of the present invention.
[0051] In the present invention, a vector refers to an artificial construct that can deliver and preferably express one or more target genes or sequences in a host cell. The vector of the present invention is not limited and can be an expression vector, a viral vector, etc. In certain embodiments, the vector comprises a target gene, a promoter, a terminator encoding an antibody of the present invention or a precursor thereof, or optionally further comprises a marker gene. The vector can use a known vector or a self-constructed vector. Known vectors include plasmid vectors, lentiviral vectors, adenoviral vectors, AAV viral vectors, etc.
[0052] In the present invention, "recombinant host cell", "host cell", "cell", "cell line", "cell culture" and other microorganisms or higher eukaryotic cell lines cultured as single-cell entities can be used interchangeably, which can be used as, or have been used as, a recipient of recombinant vectors or other transfected DNA, and include the original progeny of the transfected original cells. The vector is used to express the antibody against human L1CAM protein described in the present invention or the antibody or its functional fragment described in the present invention. The host cells useful in the present invention include, but are not limited to, eukaryotic host cells. Preferred eukaryotic host cells include, but are not limited to, mammalian host cells, insect host cells, plant host cells, fungal host cells, eukaryotic algae host cells, nematode host cells, protozoan host cells and fish host cells. Preferably, mammalian host cells include, but are not limited to, Chinese hamster ovary (CHO) cells, COS cells, Vero cells, SP2 / 0 cells, NS / 0 myeloma cells, human embryonic kidney (HEK293) cells, baby hamster kidney (BHK) cells, HeLa cells, human B cells, CV-1 / EBNA cells, L cells, 3T3 cells, HEPG2 cells, PerC6 cells or MDCK cells. Preferred fungal host cells include Aspergillus, Neurospora, Saccharomyces, Pichia, Hansenula, Schizosaccharomyces, Kluyveromyces, Yarrowia, and Candida.
[0053] The fifth aspect of the present invention provides a method for preparing the antibody or antigen-binding fragment thereof according to the first aspect of the present invention.
[0054] Furthermore, the method comprises culturing the host cell described in the fourth aspect of the present invention under conditions suitable for expressing the antibody, and optionally the method further comprises recovering the antibody or antigen-binding fragment thereof from the host cell or culture medium.
[0055] The sixth aspect of the present invention provides the use of the antibody and antigen-binding fragment thereof described in the first aspect of the present invention, the antibody derivative described in the second aspect of the present invention, the nucleic acid molecule described in the third aspect of the present invention, the vector or host cell described in the fourth aspect of the present invention in detecting L1CAM protein or neuronal exosomes for non-diagnostic purposes, in preparing a product for detecting L1CAM protein or capturing neuronal exosomes, or in preparing a product for diagnosing neurodegenerative diseases.
[0056] In the present invention, the L1CAM antibody can specifically recognize exosomes derived from neurons, and the captured neuron-derived exosomes can be used as samples for the diagnosis of neurodegenerative diseases, including but not limited to Alzheimer's disease, Parkinson's disease, and amyotrophic lateral sclerosis.
[0057] The seventh aspect of the present invention provides a method for detecting L1CAM protein or neuronal exosomes in vitro.
[0058] Furthermore, the method comprises the following steps: contacting the antibody described in the first aspect of the present invention with a sample to be tested, and detecting the formation of an immune complex between L1CAM protein or neuronal exosomes and the antibody.
[0059] The eighth aspect of the present invention provides a method for treating a disease or condition in a subject in need thereof, comprising administering to the subject the antibody or antigen-binding fragment thereof as described in the first aspect of the present invention, the antibody derivative as described in the second aspect of the present invention, the nucleic acid molecule as described in the third aspect of the present invention, the vector or host cell as described in the fourth aspect of the present invention.
[0060] Furthermore, the disease or condition includes a tumor or a neurodegenerative disease.
[0061] Furthermore, the tumors include melanoma, neuroblastoma, ovarian cancer, colon cancer, pancreatic cancer, and endometrial cancer.
[0062] Furthermore, the neurodegenerative diseases include Alzheimer's disease, Parkinson's disease, and amyotrophic lateral sclerosis.
[0063] A ninth aspect of the present invention provides a method for diagnosing a tumor or a neurodegenerative disease.
[0064] Furthermore, the method comprises contacting the antibody described in the first aspect of the present invention with a sample to be tested, and detecting the formation of an antibody immune complex.
[0065] Furthermore, the tumors include melanoma, neuroblastoma, ovarian cancer, colon cancer, pancreatic cancer, and endometrial cancer.
[0066] Furthermore, the neurodegenerative diseases include Alzheimer's disease, Parkinson's disease, and amyotrophic lateral sclerosis.
[0067] In one embodiment, the antibody or antigen-binding fragment thereof described in the first aspect of the present invention can also be connected to at least one therapeutically active substance or pharmaceutically active ingredient through a linker to form an antibody-drug conjugate (ADC). The term "antibody-drug conjugate" or "ADC" refers to an antibody or antibody fragment that is covalently coupled to a therapeutically active substance or an active pharmaceutical ingredient, so that the therapeutically active substance or active pharmaceutical ingredient is targeted to the binding target of the antibody to exhibit its pharmacological function. The therapeutically active substance or active pharmaceutical ingredient may be a cytotoxin that can kill cells (preferably cancer cells) targeted by the ADC. The covalent connection of the therapeutically active substance, active pharmaceutical ingredient or cytotoxin can be performed in a non-site-specific manner using a linker, or in a site-specific manner. The term "site-specific coupling" refers to a connection method that specifically connects a therapeutically active substance or active pharmaceutical ingredient to a specific site of an antibody. In one embodiment, the coupling is completed with the aid of a linker. In one embodiment, the antibody or antigen-binding fragment thereof described in the present invention has the effect of treating cancer, and the cancer includes but is not limited to melanoma, neuroblastoma, ovarian cancer, colon cancer, pancreatic cancer, and endometrial cancer.
[0068] In another embodiment, the antibody or its antigen-binding fragment, nucleic acid molecule, vector, host cell provided by the present invention can be included in a pharmaceutical composition, more particularly in a pharmaceutical preparation, so as to be used for various purposes according to actual needs. The pharmaceutical composition also contains a second therapeutic agent and / or optionally a pharmaceutical excipient, and the second therapeutic agent is selected from cytokines, antibodies, chemotherapeutic agents and small molecule drugs. The term "pharmaceutical composition" refers to a composition that exists in a form that allows the biological activity of the active ingredient contained therein to be effective, and does not contain additional ingredients that are unacceptably toxic to the subject to whom the composition is applied. The pharmaceutical composition, including but not limited to: carriers, diluents, adjuvants, excipients, preservatives, fillers, disintegrants, wetting agents, emulsifiers, suspending agents, sweeteners, flavoring agents, flavoring agents, antibacterial agents, antifungal agents, lubricants, dispersants, temperature-sensitive materials, temperature regulators, adhesives, stabilizers, suspending agents, etc.
[0069] In the present invention, the term "binding" or "specific binding" means that the binding effect is selective for the antigen and can be distinguished from unwanted or non-specific interactions. The ability of an antigen binding site to bind to a specific antigen can be determined by enzyme-linked immunosorbent assay (ELISA) or conventional binding assays known in the art.
[0070] In the present invention, the term "affinity" or "binding affinity" refers to the intrinsic binding ability that reflects the interaction between members of a binding pair. The affinity of a molecule X for its binding partner Y can be represented by the equilibrium dissociation constant (KD), which is the ratio of the dissociation rate constant and the association rate constant (kdis and kon, respectively). Binding affinity can be measured by common methods known in the art.
[0071] In the present invention, the term "comprising" or "including" means including the described elements, integers or steps, but does not exclude any other elements, integers or steps. In this article, when the term "comprising" or "including" is used, unless otherwise specified, the situation consisting of the described elements, integers or steps is also covered.
[0072] Beneficial effects of the present invention:
[0073] The present invention provides an antibody against human L1CAM protein, which has a strong binding activity with neuronal exosomes, can be used as an effective detection method for screening neuronal exosomes, and can be used for diagnosing neurodegenerative diseases. BRIEF DESCRIPTION OF THE DRAWINGS
[0074] Figure 1 This is the electrophoresis diagram of L1CAM protein antibody 5A8 recognizing neuronal exosomes. DETAILED DESCRIPTION
[0075] Before describing the inventive method, it should be understood that the present invention is not limited to the specific methods and experimental conditions described, because such methods and conditions can vary. It should also be understood that the terms used in the present invention are only for the purpose of describing specific embodiments, and are not intended to be restrictive, because the scope of the present invention is limited only by the appended claims.
[0076] The practice of the present invention will employ, unless otherwise indicated, conventional techniques of molecular biology (including recombinant techniques), microbiology, cell biology, biochemistry and immunology, which are within the skill of the art.
[0077] Unless otherwise defined, all technical terms and scientific terms used in the present invention have the same meaning as those generally understood by those of ordinary skill in the art to which the present invention belongs. Although any methods and materials similar to or equivalent to the methods and materials described in the present invention can be used in the practice or testing of the present invention, preferred methods and materials are now described. All publications mentioned in the present invention are incorporated into the present invention by reference in their entirety.
[0078] The present invention will be further described in detail below in conjunction with the accompanying drawings and examples. The following examples are only used to illustrate the present invention and are not intended to limit the scope of the present invention.
[0079] Example 1 Preparation of 5A8 Antibody
[0080] 1. Experimental methods
[0081] 1) Immunogen processing: The immunogen is recombinant L1CAM protein. The protein purity and molecular weight were identified by SDS-PAGE and processed by ImmunoPlus technology to enhance immunogenicity.
[0082] 2) Animal immunization: BALB / c mice were selected and immunized by conventional methods. After three immunizations, the antiserum titer was tested by indirect ELISA method, and mice with high titer were selected for subsequent experiments. Western test was used to test the recognition of antiserum to recombinant antigen.
[0083] 3) Preparation of spleen cells: Kill the mouse by cervical stenosis, remove the spleen under sterile conditions, and place it in a sterilized 90-100 mesh stainless steel net. Use a syringe to inject 3 ml of serum-free culture medium into the spleen, repeatedly aspirate several times to obtain cells, and then make a cell suspension. Inject the cell suspension into a 50 ml centrifuge tube, add 10-20 ml of culture medium, gently blow several times, and let it stand at room temperature for 5 minutes. Centrifuge (800-1000 rpm), count, and set aside.
[0084] 4) Cell fusion: Mix mouse myeloma cells and mouse spleen cells at a ratio of 1:5, centrifuge and discard the supernatant, and absorb the excess supernatant with sterile filter paper. Add 1ml of 40% PEG solution dropwise to the cell mass within 60 seconds, while gently rotating the centrifuge tube. In the rotating centrifuge tube, add 1ml of serum-free culture medium dropwise within 60 seconds, and then slowly add 20ml of serum-free culture medium within 5 minutes, centrifuge (800 rpm, 8 minutes), remove the supernatant, suspend with 10ml of complete culture medium, and gently mix. Add the cell suspension to a 96-well plate, 50 microliters per well, 37℃ CO 2 After culturing in the incubator for 24 hours, the medium was replaced with HAT selective culture medium.
[0085] 5) Post-fusion cell culture: 7-10 days after fusion, replace the medium with half of the HAT medium, and then replace the medium every 2-3 days. Hybrid cell colonies will appear after 2-3 weeks. When the colonies proliferate and grow to 1 / 3 of the well, use the indirect ELISA method to test the affinity of the monoclonal antibodies in the culture supernatant of mouse hybridoma cells.
[0086] 2. Experimental results
[0087] The anti-human L1CAM protein antibody 5A8 was screened out, and its sequence is shown below:
[0088] VH (heavy chain variable region), sequence number SEQ ID NO: 1:
[0089] EVQLQQSGPELEQPGASVKISCKASGHAFTGFNLNWVRQSNGERLEWIGNVAPYFGGTTYNQKFKDKATLTVDISSNTAYMQLKSLTSEDSAVYYCARHNDYEAWFASWGQGTLVTVSA
[0090] Among them, the sequences of the heavy chain complementary determining regions HCDR1, HCDR2, and HCDR3 are GHAFTGFN, VAPYFGGT, and ARHNDYEAWFAS, and the sequence numbers are SEQ ID NOs: 3, 4, and 5, respectively.
[0091] VL (light chain variable region), sequence number SEQ ID NO: 2:
[0092] DIVMTQGPPSIPVTPGESVSISCRSTKSLLHGNGNTYLYWFLQRPGQSPQLLIYRTSNLASGVPDRFSGSGSGTAFTLRISRVEAEDVGVYFCMQQLEYPFTFGSGTKLEIK
[0093] Among them, the sequences of the light chain complementary determining regions LCDR1, LCDR2, and LCDR3 are KSLLHGNGNTY, RTS, and MQQLEYPFT, respectively, and the sequence numbers are SEQ ID NOs: 6, 7, and 8, respectively.
[0094] The nucleotide sequence encoding antibody 5A8 is shown below:
[0095] The nucleotide sequence encoding the heavy chain variable region, sequence number SEQ ID NO:9:
[0096] GAGGTCCAGCCTGCAGCAGTCTGGACCTGAACTGGAGCAGCCTGGCGCTTCAGTGAAGATATCCTGCAAGGCTTCTGGTCATGCATTCACTGGCTTCAACTTGAACTGGGTGAGGCAGAGCAATGGAGAGCGCCTTGAGTGGATTGGCAATGTTGTCCCTTACTTTGGTGGTACTACCTA CAACCAGAAATTCAAGGACAAGGCCACATTGACTGTAGACATATCCTCCAACACAGCCTACATGCAGCTCAAGAGCCTGACATCTGAGGACTCTGCAGTCTATTACTGTGCAAGACATAATGATTACGAGGCTTGGTTCGCTTCCTGGGGCCAAGGGACTCTGGTCACTGTCTCTGCAG
[0097] Among them, the nucleotide sequences encoding the heavy chain complementary determining regions HCDR1, HCDR2, and HCDR3 are GGTCATGCATTCACTGGCTTCAAC, GTTGCTCCTTACTTTGGTGGTACT, and GCAAGACATAATGATTACGAGGCTTGGTTCGCTTCC, respectively, and the sequence numbers are SEQ ID NOs: 11, 12, and 13, respectively.
[0098] The nucleotide sequence encoding the light chain variable region, sequence number SEQ ID NO: 10:
[0099] GATATTGTGATGACTCAGGGTCCACCCTCTATACCTGTCACTCCTGGAGAGTCAGTATCCATCTCCTGCAGGTCTACTAAGAGTCTCCTACACGGTAATGGCAACACTTACTTGTATTGGTTCCTACAGAGGCCAGGCCAGTCTCCTCAGCTCCTGATATATCGGACG TCCAACCTTGCCTCAGGAGTCCCAGACAGGTTCAGTGGCAGTGGGTCAGGAACTGCTTTCACACTGAGAATCAGTAGAGTGGAGGCTGAGGATGTGGGTGTTTATTTCTGTATGCAACAGTTAGAATATCCATTCACGTTCGGCTCGGGGACAAAGTTGGAAATAAAC
[0100] Among them, the nucleotide sequences encoding the light chain variable regions LCDR1, LCDR2, and LCDR3 are AAGAGTCTCCTACACGGTAATGGCAACACTTAC, CGGACGTCC, and ATGCAACAGTTAGAATATCCATTCACG, and the sequence numbers are SEQ ID NO: 14, 15, and 16, respectively.
[0101] Example 2 Functional study of 5A8 antibody
[0102] 1. Antibodies recognize neuronal exosomes
[0103] Experimental methods: Two neuronal exosomes (NDE1 and NDE2) were used as antigens and detected with monoclonal antibody 5A8 in the supernatant of mouse hybridoma cell culture.
[0104] Experimental results: electrophoresis diagram Figure 1 As shown, a strong positive band appeared at around 50KD, indicating that the antibody has a strong binding ability to neuronal exosomes NDE1 and NDE2.
[0105] 2. Antibody recognition of recombinant protein
[0106] Experimental method: The indirect ELISA method was used to test the affinity of monoclonal antibodies in the culture supernatant of mouse hybridoma cells. The recombinant protein was used as the antigen to coat the ELISA plate, the coating antigen concentration was 1μg / ml, 100μl / well, the coating buffer was PBS (PH=7.4), and it was placed at 4℃ overnight; the next day, it was washed with PBS 3 times, 5 minutes each time, blocked with 1% BSA, 200μl was added to each well, and incubated in a 37℃ incubator for 2 hours; BSA was discarded, and cell culture supernatant containing monoclonal antibodies was added, 100μl per well; blank culture supernatant was used as negative control, incubated in a 37℃ incubator for 2 hours, the primary antibody was discarded, the washing solution was washed 5 times, GAMGoat Anti-Mouse IgG was added, and incubated in a 37℃ incubator for 1 hour; after adding the substrate for color development, the absorbance value was measured by an ELISA instrument.
[0107] Experimental results: The results are shown in Table 1. The absorbance value of the antibody is >3, which is much larger than the negative control value of 0.172, indicating that the antibody has a good affinity for the recombinant protein antigen.
[0108] Table 1 Antibody recognition of recombinant proteins
[0109]
[0110] The description of the above embodiments is only used to understand the method and core idea of the present invention. It should be pointed out that, for those skilled in the art, several improvements and modifications can be made to the present invention without departing from the principle of the present invention, and these improvements and modifications will also fall within the scope of protection of the claims of the present invention.
Claims
1. An antibody or antigen-binding fragment thereof having binding specificity to human L1CAM protein, characterized in that: The antibody or antigen-binding fragment thereof comprises a heavy chain variable region and a light chain variable region, wherein the heavy chain variable region comprises HCDR1, HCDR2 and HCDR3 in the heavy chain variable region as shown in SEQ ID NO: 1; and the light chain variable region comprises LCDR1, LCDR2 and LCDR3 in the light chain variable region as shown in SEQ ID NO: 2; wherein: The amino acid sequences of the HCDR1, HCDR2 and HCDR3 are shown as GHAFTGFN, VAPYFGGT and ARHNDYEAWFAS, respectively; The amino acid sequences of LCDR1, LCDR2 and LCDR3 are shown as KSLLHGNGNTY, RTS and MQQLEYPFT respectively.
2. The antibody or antigen-binding fragment thereof according to claim 1, characterized in that: The heavy chain variable region comprises the amino acid sequence shown in SEQ ID NO: 1; The light chain variable region comprises the amino acid sequence shown in SEQ ID NO:
2.
3. The antibody or antigen-binding fragment thereof according to claim 1, characterized in that: The antibodies include monoclonal antibodies, polyclonal antibodies, chimeric antibodies, humanized antibodies or mouse antibodies; The antigen-binding fragment includes Fab, Fab', F(ab')2, Fv or single-chain Fv antibody.
4. An antibody derivative, characterized in that: The antibody derivative comprises the antibody or antigen-binding fragment thereof according to any one of claims 1 to 3 and an antibody marker; the antibody marker comprises an enzyme, fluorescein, isotope, biotin, colloidal gold, or a chemiluminescent agent.
5. A nucleic acid molecule, characterized in that The nucleic acid molecule comprises a nucleotide sequence encoding the heavy chain variable region of the antibody or antigen-binding fragment thereof according to any one of claims 1 to 3, and a nucleotide sequence encoding the light chain variable region of the antibody or antigen-binding fragment thereof according to any one of claims 1 to 3.
6. The nucleic acid molecule according to claim 5, characterized in that The nucleic acid molecule comprises a base sequence encoding HCDR1-HCDR3 in the heavy chain variable region base sequence as shown in SEQ ID NO: 9; and The nucleic acid molecule comprises a base sequence encoding LCDR1-LCDR2 in the light chain variable region base sequence as shown in SEQ ID NO: 10; Among them, the base sequence encoding HCDR1 is GGTCATGCATTCACTGGCTTCAAC, the base sequence encoding HCDR2 is GTTGCTCCTTACTTTGGTGGTACT, and the base sequence encoding HCDR3 is GCAAGACATAATGATTACGAGGCTTGGTTCGCTTCC; the base sequence encoding LCDR1 is AAGAGTCTCCTACACGGTAATGGCAACACTTAC, the base sequence encoding LCDR2 is CGGACGTCC, and the base sequence encoding LCDR3 is ATGCAACAGTTAGAATATCCATTCACG.
7. A carrier, characterized in that The vector comprises the nucleic acid molecule according to any one of claims 5-6.
8. A host cell, characterized in that The host cell comprises the nucleic acid molecule according to any one of claims 5 to 6 or the vector according to claim 7.
9. A method for preparing the antibody or antigen-binding fragment thereof according to claim 1, characterized in that: The method comprises culturing the host cell of claim 8 under conditions suitable for expressing the antibody or antigen-binding fragment thereof.
10. The method according to claim 9, characterized in that The method further comprises recovering the antibody or antigen-binding fragment thereof from the host cell or culture medium.
11. Use of the antibody or antigen-binding fragment thereof according to any one of claims 1 to 3, the antibody derivative according to claim 4, the nucleic acid molecule according to any one of claims 5 to 6, the vector according to claim 7, or the host cell according to claim 8 in detecting L1CAM protein or neuronal exosomes for non-diagnostic purposes, in preparing a product for detecting L1CAM protein or capturing neuronal exosomes, or in preparing a product for diagnosing neurodegenerative diseases; The neurodegenerative diseases include Alzheimer's disease, Parkinson's disease, and amyotrophic lateral sclerosis.
12. A method for detecting L1CAM protein or neuronal exosomes in vitro for non-diagnostic purposes, characterized in that: The method comprises the following steps: contacting the antibody or antigen-binding fragment thereof according to any one of claims 1 to 3 with a sample to be tested, and detecting the formation of an immune complex between L1CAM protein or neuronal exosomes and the antibody or antigen-binding fragment thereof.
Citation Information
Patent Citations
Antibody binding specifically to human and mouse L1cam protein, and use therefor
CN104936984A
Recombinant anti-CD171 bispecific antibody and capture method of nerve-derived exosome
CN112010980A
Novel anti-L1CAM antibody
CN118176215A
Humanized antibody against human l1CAM and method for preparing antibody
KR1020140026045A
